And then you add $8.3M with (one-off) share expense from the director sell to give in your case $10m- $11M. Without the director sell, my assumptions will be like yours with $1M-$3M loss. Have a look at the 1st half yearly of FY20 The number circled in red will come through in the FY20 report.
Around $3M gov grant recognised this FY20, R&D grant - $1.5M (I think only 1 of the $798K receipts have been recorded soo another on the way?). SaaS revenues of ~ $300k (I assume as 1/2 beds convert to government trial, where RAC does not pay for beds with cognitive impaired residents). So around $4.8M when you add up the revenues.
Costs being COGS, R&D, S&M, Product development. To make a general assumption $400K/month makes sense so around $5M in expenses. Then you add share based expense of $8.3M to make $13.3M in total expense.
When you do the rough calc ~ $4.8M - $13.3M = a loss of around $8.5M (Giving the optimistic case of a loss at $7M is a bit of a stretch when I now think about it )
In terms of cash flow, which is the key metric that matters of all companies right now, sitting on $6.4M cash. Assuming Painchek streamlined costs this quarter (Q4FY20) from $1.6M in Q3FY20 to $1.4M, then net cashflow should be $650k.
In this quarter there was $1.25M gov grant. Assuming $0.8M R&D grant (was also given, not confirmed) then cash inflow this quarter would be $2.05M. Hence net cashflow = $2.05M - $1.4M = $0.65M = $650k.
Cashflow at FY20 expected to be $7.05M
Those are my assumptions for FY20 numbers
PCK Price at posting:
12.5¢ Sentiment: Hold Disclosure: Held
The number circled in red will come through in the FY20 report.
